Koji Murakami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Koji Murakami has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
Makoto Hino
Hiroshima Institute of Technology
6 shared publicationsTsutomu Tamada
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
6 shared publicationsTeruto Kanadani
Okayama University of Science
5 shared publicationsHisatoshi Sugiura
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
4 shared publicationsMasakazu Ichinose
Osaki Citizen Hospital, Osaki, Japan
4 shared publicationsMasayuki Nara
National Hospital Organization Akita National Hospital, Yurihonjo, Japan
4 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Springer Nature in BMC Pulmonary Medicine
STAT1 signaling in sarcoidosis granulomas and its association with organ-specific clinical course
Background: The clinical course of sarcoidosis, a systemic disease of unknown etiology, varies from spontaneous resolution to progressive multi-organ dysfunction. To clarify the pathogenesis, omics-based analyses of patient samples have been conducted. However, analyses of mechanisms underlying granuloma development and persistence related to disease progression remain limited. This study aimed to identify immunological events within sarcoidosis granulomas and to explore their association with the subsequent clinical course of the affected organs. Methods: Laser-microdissected granuloma and non-granuloma regions from lung tissues of five patients were analyzed using RNA sequencing, followed by differential gene expression and pathway analyses. Immunohistochemistry for pSTAT1 and pSTAT3 was performed on pulmonary and extrapulmonary tissues from 20 patients; organ-specific analyses were subsequently performed in 30 specimens from 15 corticosteroid-naïve patients. Associations between granuloma pSTAT1 positivity and organ-specific clinical course were assessed using an unadjusted Mann–Whitney U test and a logistic generalized estimating equation model accounting for multiple specimens from the same patient. Results: Comparative analysis identified 1,129 differentially expressed genes between granuloma and non-granuloma regions. The granuloma region showed high expression of IFN-γ–STAT1 pathway-related genes. Immunohistochemical analysis revealed that pSTAT1-positive nuclei were consistently observed within granuloma lesions in all organs. Higher granuloma pSTAT1 positivity was observed in organs with subsequent disease progression. In the unadjusted analysis, pSTAT1 positivity was significantly higher in progressive than in stable/improved specimens ( P = 0.030). In a logistic generalized estimating equation model accounting for within-patient clustering, each 10-percentage-point increase in pSTAT1 positivity was associated with higher odds of subsequent organ-specific progression (OR, 2.86; 95% CI, 0.94–8.76), although the association did not reach statistical significance after small-sample correction ( P = 0.062). Conclusions: IFN-γ–STAT1 signaling was activated within sarcoidosis granulomas, and higher granuloma pSTAT1 positivity was observed in organs with progressive clinical courses in this exploratory cohort. These findings support further investigation of granuloma-localized STAT1 signaling in larger prospective studies. Trial registration number: Not applicable.
- 21 October 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Open AccessSTAT1 signaling in sarcoidosis granulomas and its association with organ-specific clinical course
Background: The clinical course of sarcoidosis, a systemic disease of unknown etiology, varies from spontaneous resolution to progressive multi-organ dysfunction. To clarify the pathogenesis, omics-based analyses of patient samples have been conducted. However, analyses of mechanisms underlying granuloma development and persistence related to disease progression remain limited. This study aimed to identify immunological events within sarcoidosis granulomas and to explore their association with the subsequent clinical course of the affected organs. Methods: Laser-microdissected granuloma and non-granuloma regions from lung tissues of five patients were analyzed using RNA sequencing, followed by differential gene expression and pathway analyses. Immunohistochemistry for pSTAT1 and pSTAT3 was performed on pulmonary and extrapulmonary tissues from 20 patients; organ-specific analyses were subsequently performed in 30 specimens from 15 corticosteroid-naïve patients. Associations between granuloma pSTAT1 positivity and organ-specific clinical course were assessed using an unadjusted Mann–Whitney U test and a logistic generalized estimating equation model accounting for multiple specimens from the same patient. Results: Comparative analysis identified 1,129 differentially expressed genes between granuloma and non-granuloma regions. The granuloma region showed high expression of IFN-γ–STAT1 pathway-related genes. Immunohistochemical analysis revealed that pSTAT1-positive nuclei were consistently observed within granuloma lesions in all organs. Higher granuloma pSTAT1 positivity was observed in organs with subsequent disease progression. In the unadjusted analysis, pSTAT1 positivity was significantly higher in progressive than in stable/improved specimens ( P = 0.030). In a logistic generalized estimating equation model accounting for within-patient clustering, each 10-percentage-point increase in pSTAT1 positivity was associated with higher odds of subsequent organ-specific progression (OR, 2.86; 95% CI, 0.94–8.76), although the association did not reach statistical significance after small-sample correction ( P = 0.062). Conclusions: IFN-γ–STAT1 signaling was activated within sarcoidosis granulomas, and higher granuloma pSTAT1 positivity was observed in organs with progressive clinical courses in this exploratory cohort. These findings support further investigation of granuloma-localized STAT1 signaling in larger prospective studies. Trial registration number: Not applicable.
- 29 November 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (1) , 20-26
Severity and prognosis of COVID-19 complicated by autoimmune pulmonary alveolar proteinosis
- 29 November 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (1) , 20-26
Severity and prognosis of COVID-19 complicated by autoimmune pulmonary alveolar proteinosis
- 19 April 2023
- Published by Elsevier in Respiratory Investigation
- Vol. 61 (4) , 454-459
Use of the neutrophil-to-lymphocyte ratio and an oxygen requirement to predict disease severity in patients with COVID-19
- 19 April 2023
- Published by Elsevier in Respiratory Investigation
- Vol. 61 (4) , 454-459
Use of the neutrophil-to-lymphocyte ratio and an oxygen requirement to predict disease severity in patients with COVID-19
- 20 January 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (4) , 422-426
Diagnostic significance of secondary bacteremia in patients with COVID-19
- 20 January 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (4) , 422-426
Diagnostic significance of secondary bacteremia in patients with COVID-19
- 1 January 2023
- Published by Japan Society of Mechanical Engineers in The Proceedings of the Dynamics & Design Conference
- Vol. 2023, 313
Estimation of Excitation Forces on a rotary tool
Monitoring technology such as predictive maintenance and anomality detection during cutting process has been required. A wireless tool holder with acceleration sensors has been developed for monitoring tool vibration. For advancing functionally of the device, we have been proposed a method using inverse filters for estimating cutting force and torque from acceleration sensor signals during machining. In this study, excitation forces (x direction force, y direction force) on a tool mounted on the holder of machining center were estimated by the proposed method. Firstly, inverse filters were determined from single-input, single-output signals by excitation experiment on non-operating state. Secondly, the proposed method was examined by estimating an impulse signal.
- 1 January 2023
- Published by Japan Society of Mechanical Engineers in The Proceedings of the Dynamics & Design Conference
- Vol. 2023, 313
Estimation of Excitation Forces on a rotary tool
Monitoring technology such as predictive maintenance and anomality detection during cutting process has been required. A wireless tool holder with acceleration sensors has been developed for monitoring tool vibration. For advancing functionally of the device, we have been proposed a method using inverse filters for estimating cutting force and torque from acceleration sensor signals during machining. In this study, excitation forces (x direction force, y direction force) on a tool mounted on the holder of machining center were estimated by the proposed method. Firstly, inverse filters were determined from single-input, single-output signals by excitation experiment on non-operating state. Secondly, the proposed method was examined by estimating an impulse signal.
- Open Access
- 1 January 2023
- Published by Japan Welding Society in QUARTERLY JOURNAL OF THE JAPAN WELDING SOCIETY
- Vol. 41 (3) , 217-224
一般溶接用鋼における大ひずみ領域での繰返し真応力真ひずみ関係
Cyclic true stress - true strain curves were obtained using general-purpose shipbuilding steel in the large strain region. Test methods are incremental step test and static tensile test after cyclic loading. The stress-strain curves for static and cyclic loading were compared to investigate the cause of the difference between each other. A simple method for estimating the cyclic stress-strain curves was proposed. The diameter and curvature of the smallest cross-section of the specimen were measured using telecentric measurement device, and the true stress - true strain curve was obtained using the Bridgman correction method. Using the measurement method, cyclic stress-strain diagrams were obtained in the region where the true strain exceeded 1% by performing cyclic tensile tests using the incremental step method and static tensile tests after cyclic loading. The influence of the test method and maximum displacement conditions on the cyclic stress-strain curve was small within the scope of this study. There was little difference in the elongation between the static tensile test and the static tensile test after cyclic loading. The difference in yield stress between static and cyclic loading was discussed in terms of macro-yield mechanisms at intergranular and transgranular. A simple method for estimating cyclic stress-strain curves from a static stress-strain curve was proposed. The specimens used in this study are general-purpose shipbuilding steels, and the results should be applicable to similar steels for welding and structures.
- 1 January 2023
- Published by Japan Welding Society in QUARTERLY JOURNAL OF THE JAPAN WELDING SOCIETY
- Vol. 41 (3) , 217-224
Open Access一般溶接用鋼における大ひずみ領域での繰返し真応力真ひずみ関係
Cyclic true stress - true strain curves were obtained using general-purpose shipbuilding steel in the large strain region. Test methods are incremental step test and static tensile test after cyclic loading. The stress-strain curves for static and cyclic loading were compared to investigate the cause of the difference between each other. A simple method for estimating the cyclic stress-strain curves was proposed. The diameter and curvature of the smallest cross-section of the specimen were measured using telecentric measurement device, and the true stress - true strain curve was obtained using the Bridgman correction method. Using the measurement method, cyclic stress-strain diagrams were obtained in the region where the true strain exceeded 1% by performing cyclic tensile tests using the incremental step method and static tensile tests after cyclic loading. The influence of the test method and maximum displacement conditions on the cyclic stress-strain curve was small within the scope of this study. There was little difference in the elongation between the static tensile test and the static tensile test after cyclic loading. The difference in yield stress between static and cyclic loading was discussed in terms of macro-yield mechanisms at intergranular and transgranular. A simple method for estimating cyclic stress-strain curves from a static stress-strain curve was proposed. The specimens used in this study are general-purpose shipbuilding steels, and the results should be applicable to similar steels for welding and structures.
- Open Access
- 15 December 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 61 (2) , 247-253
Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
- 15 December 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 61 (2) , 247-253
Open AccessAntibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
- Open Access
- 5 September 2022
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 9 (1) , e001332
Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy
Rational Corticosteroid therapy plays a key role in the treatment of COVID-19 patients with respiratory failure. However, a rebound phenomenon after steroid cessation rarely occurs. Here, we investigated the clinical features of patients with rebound after steroid therapy. Methods In total, 84 patients with COVID-19 treated with corticosteroids were enrolled and analysed retrospectively. A rebound was defined as when a patient’s respiratory status deteriorated after the cessation of corticosteroid therapy, without secondary bacterial infection. Results Subjects in the rebound group were more likely to having severe respiratory failure than those in the non-rebound group. While the duration of steroid therapy was longer in the rebound group (8 days vs 10 days, p=0.0009), the dosage of steroid and the timing of the start or termination of steroid therapy did not show any differences between the two groups (p=0.17 and 0.68, respectively). The values of soluble interleukin-2 receptor (sIL-2R) at the baseline and the values of C reactive protein (CRP) or lactate dehydrogenase (LDH) at the end of steroid therapy were significantly higher in the rebound group (937 vs 1336 U/mL; p=0.002, 0.63 vs 3.96 mg/dL; p=0.01 and 278 vs 451 IU/mL; p=0.01, respectively). No patient in the rebound group suffered from thromboses, and the causes of death were exacerbation of COVID-19, ventilator-associated pneumonia or sepsis. The prediction model using baseline features for the rebound phenomenon included four variables of age >68 years, required supplemental oxygen >5 L/min, lymphocyte counts 1146 U/mL. The discrimination ability of this model was 0.906 (0.755–0.968). Conclusion These findings suggest that severe respiratory failure has a higher risk for the rebound phenomenon after the cessation of corticosteroids, and the values of sIL-2R, LDH and CRP are useful to assess the probability of developing rebound. A multivariate model was developed to predict rebound risk, which showed acceptable discrimination ability.
- 5 September 2022
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 9 (1) , e001332
Open AccessClinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy
Rational Corticosteroid therapy plays a key role in the treatment of COVID-19 patients with respiratory failure. However, a rebound phenomenon after steroid cessation rarely occurs. Here, we investigated the clinical features of patients with rebound after steroid therapy. Methods In total, 84 patients with COVID-19 treated with corticosteroids were enrolled and analysed retrospectively. A rebound was defined as when a patient’s respiratory status deteriorated after the cessation of corticosteroid therapy, without secondary bacterial infection. Results Subjects in the rebound group were more likely to having severe respiratory failure than those in the non-rebound group. While the duration of steroid therapy was longer in the rebound group (8 days vs 10 days, p=0.0009), the dosage of steroid and the timing of the start or termination of steroid therapy did not show any differences between the two groups (p=0.17 and 0.68, respectively). The values of soluble interleukin-2 receptor (sIL-2R) at the baseline and the values of C reactive protein (CRP) or lactate dehydrogenase (LDH) at the end of steroid therapy were significantly higher in the rebound group (937 vs 1336 U/mL; p=0.002, 0.63 vs 3.96 mg/dL; p=0.01 and 278 vs 451 IU/mL; p=0.01, respectively). No patient in the rebound group suffered from thromboses, and the causes of death were exacerbation of COVID-19, ventilator-associated pneumonia or sepsis. The prediction model using baseline features for the rebound phenomenon included four variables of age >68 years, required supplemental oxygen >5 L/min, lymphocyte counts 1146 U/mL. The discrimination ability of this model was 0.906 (0.755–0.968). Conclusion These findings suggest that severe respiratory failure has a higher risk for the rebound phenomenon after the cessation of corticosteroids, and the values of sIL-2R, LDH and CRP are useful to assess the probability of developing rebound. A multivariate model was developed to predict rebound risk, which showed acceptable discrimination ability.
- Open Access
- 14 March 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-11
Urine autotaxin levels reflect the disease activity of sarcoidosis
Since the clinical outcome of patients with sarcoidosis is still unpredictable, a good prognostic biomarker is necessary. Autotaxin (ATX) and phosphatidylserine-specific phospholipase A1 (PS-PLA1) function as main enzymes to produce lysophospholipids (LPLs), and these enzymes are attracting attention as useful biomarkers for several chronic inflammatory diseases. Here, we investigated the relationships between LPLs-producing enzymes and the disease activity of sarcoidosis. In total, 157 patients with sarcoidosis (active state, 51%) were consecutively enrolled. Using plasma or urine specimens, we measured the values of LPLs-producing enzymes. Urine ATX (U-ATX) levels were significantly lower in the active state compared to those in the inactive state, while the plasma ATX (P-ATX) and PS-PLA1 levels showed no significant difference between these two states. Concerning the comparison with existing clinical biomarkers for sarcoidosis, U-ATX showed a weak negative correlation to ACE, P-ATX a weak positive correlation to both ACE and sIL-2R, and PS-PLA1 a weak positive one to sIL-2R. Notably, only the U-ATX levels inversely fluctuated depending on the status of disease activity whether OCS had been used or not. These findings suggest that U-ATX is likely to be a novel and useful molecule for assessing the disease activity of sarcoidosis.
- 14 March 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-11
Open AccessUrine autotaxin levels reflect the disease activity of sarcoidosis
Since the clinical outcome of patients with sarcoidosis is still unpredictable, a good prognostic biomarker is necessary. Autotaxin (ATX) and phosphatidylserine-specific phospholipase A1 (PS-PLA1) function as main enzymes to produce lysophospholipids (LPLs), and these enzymes are attracting attention as useful biomarkers for several chronic inflammatory diseases. Here, we investigated the relationships between LPLs-producing enzymes and the disease activity of sarcoidosis. In total, 157 patients with sarcoidosis (active state, 51%) were consecutively enrolled. Using plasma or urine specimens, we measured the values of LPLs-producing enzymes. Urine ATX (U-ATX) levels were significantly lower in the active state compared to those in the inactive state, while the plasma ATX (P-ATX) and PS-PLA1 levels showed no significant difference between these two states. Concerning the comparison with existing clinical biomarkers for sarcoidosis, U-ATX showed a weak negative correlation to ACE, P-ATX a weak positive correlation to both ACE and sIL-2R, and PS-PLA1 a weak positive one to sIL-2R. Notably, only the U-ATX levels inversely fluctuated depending on the status of disease activity whether OCS had been used or not. These findings suggest that U-ATX is likely to be a novel and useful molecule for assessing the disease activity of sarcoidosis.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
The clinical significance of plasma and urine lysophospholipids-producing enzymes in patients with sarcoidosis
Background: Sarcoidosis has wide variety of clinical course, ranging from spontaneous remission to severe dysfunction of major organs. However, no reliable prognostic biomarker is established by now. Lysophospholipids (LysoPL) is one of the important bioactive phospholipid mediators and seems to be a useful serum biomarker for detection of several cancers or chronic liver diseases. Aims: The aim of this study is to demonstrate relationships between lysoPL producing enzymes (autotaxin [ATX] and phosphatidylserine-specific phospholipase A1 [PS-PLA1]) and clinical features in patients with sarcoidosis. Methods: The total of 158 patients (Male; 36%, mean age; 53 years-old) with sarcoidosis were consecutively enrolled from Tohoku University Hospital between October 1, 2014 and Dec 31, 2018. All patients met the ATS/ERS/WASOG criteria for a diagnosis of sarcoidosis. Patients taking systemic corticosteroid therapy in the 12 months before study entry were excluded. Disease activity were evaluated by two independent pulmonologists. Both ATX and PS-PLA1 concentrations in plasma and urine samples were simultaneously analyzed. Results: Plasma ATX values were significantly higher in patients with skin lesions (1.07mg/L vs. 0.95mg/L, pp<0.01). Plasma ATX values had significant positive correlations with ACE and sIL-2R values. Plasma PS-PLA1 values were positively correlated with sIL-2R. Conclusions: LysoPL producing enzymes were partially correlated with existing biomarkers and disease activity. These findings suggested ATX and PS-PLA1 could be novel biomarkers of sarcoidosis.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
The clinical significance of plasma and urine lysophospholipids-producing enzymes in patients with sarcoidosis
Background: Sarcoidosis has wide variety of clinical course, ranging from spontaneous remission to severe dysfunction of major organs. However, no reliable prognostic biomarker is established by now. Lysophospholipids (LysoPL) is one of the important bioactive phospholipid mediators and seems to be a useful serum biomarker for detection of several cancers or chronic liver diseases. Aims: The aim of this study is to demonstrate relationships between lysoPL producing enzymes (autotaxin [ATX] and phosphatidylserine-specific phospholipase A1 [PS-PLA1]) and clinical features in patients with sarcoidosis. Methods: The total of 158 patients (Male; 36%, mean age; 53 years-old) with sarcoidosis were consecutively enrolled from Tohoku University Hospital between October 1, 2014 and Dec 31, 2018. All patients met the ATS/ERS/WASOG criteria for a diagnosis of sarcoidosis. Patients taking systemic corticosteroid therapy in the 12 months before study entry were excluded. Disease activity were evaluated by two independent pulmonologists. Both ATX and PS-PLA1 concentrations in plasma and urine samples were simultaneously analyzed. Results: Plasma ATX values were significantly higher in patients with skin lesions (1.07mg/L vs. 0.95mg/L, pp<0.01). Plasma ATX values had significant positive correlations with ACE and sIL-2R values. Plasma PS-PLA1 values were positively correlated with sIL-2R. Conclusions: LysoPL producing enzymes were partially correlated with existing biomarkers and disease activity. These findings suggested ATX and PS-PLA1 could be novel biomarkers of sarcoidosis.